AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a fully-integrated biopharmaceutical company, recently announced a significant milestone in its mission to combat migraine disorders. On September 24, 2024, the United States Patent and Trademark Office issued U.S. Patent No. 12,097,183, titled “Pharmaceutical Composition for Treating Migraine.” This patent specifically claims the use of a pre-filled autoinjector containing Zembrace® SymTouch® for the subcutaneous treatment of migraines, ensuring protection for the innovative therapy until 2036, barring any potential patent term extensions.
Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, expressed enthusiasm regarding the new patent, stating, “We are excited to announce the issuance of this additional patent, providing further protection for our exclusive marketing and sale of FDA-approved Zembrace® for the treatment of migraines.” This development reinforces the company’s commitment to providing effective alternatives for those suffering from this debilitating condition.
Zembrace® SymTouch® offers a non-oral solution for migraine sufferers. Unlike traditional oral medications, which must pass through the digestive system, Zembrace® is designed for subcutaneous administration, allowing for quicker onset of relief. This could be especially beneficial for patients who often experience symptoms so severe that they cannot tolerate oral medications.
In conjunction with this patent announcement, Tonix has launched an educational campaign titled “Does Your Migraine Pill Work Every Time?” This initiative aims to raise awareness among patients and healthcare providers about the advantages of non-oral migraine treatments, including injectables and nasal sprays. The campaign seeks to highlight that these options can provide faster relief, often within just 10 minutes, making them vital for individuals who need immediate symptom management.
A key focus of Tonix’s educational efforts is gastroparesis, a condition that can complicate migraine management. Gastroparesis slows or obstructs the stomach's ability to empty, which can significantly delay the absorption of oral migraine medications. This often results in inconsistent relief and can frustrate patients who rely on these treatments.
Dr. Lederman emphasized Tonix’s dedication to empowering both patients and healthcare providers. “We hope to inspire patients to optimize their migraine treatment plan with non-oral medications,” he said. By educating patients about the potential benefits of injectable and nasal treatments, Tonix aims to improve the overall quality of life for those affected by migraines.
The issuance of the new patent for Zembrace® SymTouch® is a promising step forward in migraine treatment options. By combining innovative delivery methods with robust educational initiatives, Tonix Pharmaceuticals is poised to enhance the management of migraines, ultimately providing patients with the relief they desperately seek. As the company continues to advocate for better treatment solutions and patient education, it reaffirms its commitment to addressing the complex challenges associated with migraine disorders.
